Investor Relations

Company Overview

Developing the next generation FDA approved synthetic THC analog

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is an early-stage life sciences company focused on the development and commercialization of MIRA1a, a synthetic analog of THC. MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and neuropathic pain without impurities or the negative side effects associated with cannabis plant extracts.